Skip to main content

Clariscan Side Effects

Generic name: gadoterate meglumine

Medically reviewed by Drugs.com. Last updated on Jan 22, 2024.

Note: This document contains side effect information about gadoterate meglumine. Some dosage forms listed on this page may not apply to the brand name Clariscan.

Applies to gadoterate meglumine: intravenous solution.

Warning

Intravenous route (Solution)

Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with noncontrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. The risk for NSF appears highest among patients with chronic, severe kidney disease (GFR less than 30 mL/min/1.73m(2)), or acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (eg, older than 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.

Serious side effects of Clariscan

Along with its needed effects, gadoterate meglumine (the active ingredient contained in Clariscan) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking gadoterate meglumine:

Rare

Incidence not known

Other side effects of Clariscan

Some side effects of gadoterate meglumine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Rare

Incidence not known

For Healthcare Professionals

Applies to gadoterate meglumine: intravenous solution.

General

-[Ref]

References

1. Product Information. Dotarem (gadoteric acid). Guerbet LLC. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.